Australia Antibody Drug Conjugates Market Size & Outlook
Australia antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Australia antibody drug conjugates market highlights
- The Australia antibody drug conjugates market generated a revenue of USD 44.4 million in 2021 and is expected to reach USD 158.6 million by 2030.
- The Australia market is expected to grow at a CAGR of 15.2% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 44.4 million |
| Market revenue in 2030 | USD 158.6 million |
| Growth rate | 15.2% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Australia accounted for 0.8% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 863.8 million by 2030.
Blood cancer was the largest segment with a revenue share of 58.56% in 2021. Horizon Databook has segmented the Australia antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Australia, with an age-standardized rate of 452.4 per 100,000 population, has one of the highest rates of cancers in the world, as per the International Agency for Research on Cancer. Given this high prevalence of cancer, the country has focused on providing payment assistance for certain ADC drugs.
For instance, Adcetris, indicated for the treatment of Hodgkin’s lymphoma, has been publicly funded through the Pharmaceutical Benefits Scheme (PBS) to ease out-of-pocket expenditure by the public. Australia has one of the highest ASRs of Hodgkin’s lymphoma in the world, with further growth projected in its rapidly increasing elderly population.
Australian firms such as Avipep Therapeutics have ADC drugs indicated for multiple adenocarcinomas, Hodgkin’s lymphoma, cutaneous lymphoma, systematics anaplastic large cell lymphoma, and TBA in their research pipeline. Products such as Trodelvy are currently under regulatory review for the treatment of TNBC.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia antibody drug conjugates market size, by application, 2018-2030 (US$M)
Australia Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
